Investigating Second-Line Treatment Options for Myelofibrosis

Rami Komrokji, MD, discusses what the MOST study's results mean for investigating second-line treatment options in myelofibrosis.

In an interview with Pharmacy Times, Rami Komrokji, MD, clinical director of malignant hematology and department lead clinical investigator at the H. Lee Moffitt Cancer Center and Research Institute, spoke about the MOST study and what its findings mean for investigating second-line treatment options for myelofibrosis. Komrokji presented at the 62nd American Society of Hematology Annual Meeting and Exposition on ‘To Treat or Not to Treat? Understanding Treatment Patterns in Patients with Lower-Risk Myelofibrosis at the Time of Enrollment in the MOST Study.’